Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02709161 · ClinicalTrials.gov registry record · NA
Effects of Amygdala Neurofeedback on Depressive Symptoms
A NA study, sponsored by Kymberly Young.
- Terminated
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT02709161: Clinical Trial NA study, sponsored by Kymberly Young.
NCT02709161 is a NA study that was terminated before completion, run by Kymberly Young. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02709161, a NA study, was terminated before completion, sponsored by Kymberly Young.
- TERMINATED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the clinical efficacy of augmenting cognitive-behavioral therapy with real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) training to increase the amygdala's response to positive autobiographical memories.
Primary Outcome
The Beck Depression Inventory is a self-report questionnaire consisting of 21 questions assessing depressive symptoms. Scores can range from 0-63 with higher scores indicating more severe depression.
Interventions
- DEVICE real-time fMRI neurofeedback: Amygdala
- DEVICE real-time fMRI neurofeedback: HIPS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-10 |
| Est. Completion | 2020-04-01 |
| Phase | NA |
Why NCT02709161 stopped before completion
NCT02709161 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which real-time fMRI neurofeedback: Amygdala is the first listed.
NCT02709161 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02709161 about?
NCT02709161 is a clinical study titled "Effects of Amygdala Neurofeedback on Depressive Symptoms". The purpose of this study is to determine the clinical efficacy of augmenting cognitive-behavioral therapy with real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) training to increase the amygdala's response to positive autobiographical memories.
What is the current status of trial NCT02709161?
This trial is currently terminated. It is a NA study. The enrollment target is 36 participants. The study started on 2016-10. Estimated completion is 2020-04-01.
What interventions are being tested in trial NCT02709161?
The interventions under investigation include: real-time fMRI neurofeedback: Amygdala (DEVICE), real-time fMRI neurofeedback: HIPS (DEVICE).
Who is sponsoring clinical trial NCT02709161?
This trial is sponsored by Kymberly Young, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02709161's enrollment target sits among peer trials
36 1541st of 2000 higher than 437 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia